VivoSim Labs, Inc. (VIVS): EBITDA
-$11.27M
Year ended 2026-03-31
-$11.14M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | -$11.27M | n/m | 2026-07-14, From 2025-04-01 |
| 2025-03-31 | -$12.35M | n/m | 2026-07-14, From 2024-04-01 |
| 2024-03-31 | -$14.81M | n/m | 2025-06-05, From 2023-04-01 |
| 2023-03-31 | -$17.44M | n/m | 2024-05-31, From 2022-04-01 |
| 2022-03-31 | -$11.34M | n/m | 2023-07-14, From 2021-04-01 |
| 2021-03-31 | -$16.79M | n/m | 2022-06-10, From 2020-04-01 |
| 2020-03-31 | -$20.33M | n/m | 2021-06-15, From 2019-04-01 |
| 2019-03-31 | -$26.29M | n/m | 2020-05-28, From 2018-04-01 |
| 2018-03-31 | -$34.00M | n/m | 2019-06-03, From 2017-04-01 |
| 2017-03-31 | -$37.43M | n/m | 2018-05-31, From 2016-04-01 |
| 2016-03-31 | -$37.83M | n/m | 2018-05-31, From 2015-04-01 |
| 2015-03-31 | -$29.82M | n/m | 2017-06-07, From 2014-04-01 |
| 2014-03-31 | -$20.26M | n/a | 2016-06-09, From 2013-04-01 |
| No annual figure between 2012-12-31 and 2014-03-31. | |||
| 2012-12-31 | -$9.12M | n/m | 2015-06-09, From 2012-01-01 |
| 2011-12-31 | -$2.24M | n/a | 2014-06-10, From 2011-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | -$11.27M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$76.96M | n/m |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | -$48.60M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$48.05M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$158.43M | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | -$24.43M | n/m |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | -$132.54M | n/m |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | -$6.12M | n/m |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$66.94M | n/m |
Compare VIVS, ATYR, CRDF, IMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗